ACROSS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
What it measured
Main measures
the change from baseline (D2201 baseline) in EDSS score at the 10-year follow-up visit
Disability progression
Other measures (1)
Proportion of patients with disability progression at 10 years will be summarized
Disability progression
Who could take part
Relapsing MS
Inclusion: 1. Written informed consent must be obtained before any assessment is performed Exclusion: Patients not meeting the inclusion criteria are excluded.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To investigate whether continuous use of fingolimod over 10 years reduces the progression of disability, as measured by the mean Expanded Disability Status Scale (EDSS) score, compared to shorter treatment duration
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
Started
Feb 2014
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error